Evidence map›Paper›PMID 38115672›Full record

ReviewImmunological reviews2024

Understanding very early onset inflammatory bowel disease (VEOIBD) in relation to inborn errors of immunity.

Caroline H T Hall, Edwin F de Zoeten

Open access · bronzeAbstract readCase ReportsReview
In one paragraph

Review in Immunological reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Case Report: NovelFrontiers in immunology · 2025
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Caroline H T HallMucosal Inflammation Program University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-7100-3423
Edwin F de ZoetenMucosal Inflammation Program University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-0946-9759
University of Colorado Anschutz Medical Campus · US

Funding

Institutional Career Development CoreKL2TR002534 · NCATS · UNIVERSITY OF COLORADO DENVER · PI BURNHAM, ELLEN L · 2018 to 2022
$4.6M
CTSA K12 Program at University of Colorado DenverK12TR004412 · NCATS · UNIVERSITY OF COLORADO DENVER · PI ELLEN L BURNHAM · 2024 to 2026
$3.2M
microRNA-dependent regulation of intestinal T-cells²R01DK111856 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DE ZOETEN, EDWIN FULCO · 2018 to 2022
$1.7M
NCATS NIH HHS K12 TR004412NCATS NIH HHS KL2 TR002534NIDDK NIH HHS R01 DK111856NIDDK NIH HHS R01DK111856NIH HHS KL2 TR002534
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD) are multifactorial diseases which are caused by the combination of genetic predisposition, exposure factors (environmental and dietary), immune status, and dysbiosis. IBD is a disease which presents at any age, ranging from newborns to the elderly. The youngest of the pediatric IBD population have a more unique presentation and clinical course and may have a different etiology. Very early onset IBD (VEOIBD) patients, designated as those diagnosed prior the age of 6, have distinct features which are more frequent in this patient population including increased incidence of monogenetic causes for IBD (0%-33% depending on the study). This proportion is increased in the youngest subsets, which is diagnosed prior to the age of 2. To date, there are approximately 80 monogenic causes of VEOIBD that have been identified and published. Many of these monogenic causes are inborn errors of immunity yet the majority of VEOIBD patients do not have an identifiable genetic cause for their disease. In this review, we will focus on the clinical presentation, evaluation, and monogenic categories which have been associated with VEOIBD including (1) Epithelial cell defects (2) Adaptive immune defects, (3) Innate Immune/Bacterial Clearance and Recognition defects, and (4) Hyperinflammatory and autoinflammatory disorders. We will highlight differential diagnosis of VEOIBD presentations, as well as evaluation and treatment, which will be helpful for those who study and care for VEOIBD patients outside of the pediatric gastroenterology field. This is a fast-moving field of research which has grown significantly based on knowledge that we gain from our patients. These scientific findings have identified novel mucosal biology pathways and will continue to inform our understanding of gastrointestinal biology.

Indexed as

Inflammatory Bowel DiseasesAgedAge of OnsetChildGenetic Predisposition to DiseaseHumansInfant, Newbornautoinflammatory processepithelial cellsinflammatory bowel diseasemonogenicT cellsvery early onset inflammatory bowel disease

Identifiers

PMID38115672
PMCPMC11044353
OpenAlexW4390011483

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.